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Abstract
Purpose Vercirnon is a CCR9 chemokine receptor antagonist
being developed for the treatment of Crohn’s disease. As a
variety of concomitant medications are often required for the
treatment of Crohn’s disease, it is important to characterise the
drug interaction profile of vercirnon. To confirm the results of
previous in vitro inhibition studies, this study assessed the
in vivo effect of vercirnon on the activity of cytochrome P450
enzymes (CYP3A4, CYP2C19 and CYP2C8) and drug trans-
port proteins (BCRP and OATP1B1) using probe substrates.
Methods This was an open-label, single-sequence, repeat-
dose study conducted in 24 healthy adult subjects. On days
1–4, subjects received probe substrates (midazolam, pioglita-
zone, omeprazole and rosuvastatin; in that order), followed by
administration of vercirnon 500 mg twice daily (BID) on days
5–14. On days 11–14, in addition to vercirnon 500 mg BID,
subjects also received probe substrates as on days 1–4. Blood
samples were collected for pharmacokinetic analysis of probe
substrates, vercirnon and two of its metabolites.
Results Geometric least-squares mean ratios (90 % confi-
dence interval) of area under the concentration-time curve
from time zero to infinity for probe administered with
vercirnon (test) compared with probe alone (reference) for
midazolam, pioglitazone, omeprazole and rosuvastatin were
0.92 (0.85, 0.99), 1.01 (0.95, 1.07), 0.99 (0.76,1.31) and
0.98 (0.88, 1.09), respectively.
Conclusions Co-administration of probe substrates midazo-
lam, pioglitazone, omeprazole, and rosuvastatin following
repeat dosing of vercirnon 500 mg BID demonstrated
vercirnon had no clinically significant effect on CYP3A4,
CYP2C8, CYP2C19 enzyme activity or BCRP or OATP1B1
transporter activity.
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Introduction
Vercirnon (formerly CCX282-B or GSK1605786) is a highly
potent, orally active, chemokine receptor antagonist whose
single target is the G-protein–coupled receptor CCR9,
which has been implicated in the aetiology of inflammatory
bowel diseases such as Crohn’s disease [1–4]. Crohn’s
disease is a chronic, idiopathic, relapsing inflammatory dis-
order of the gastrointestinal (GI) tract associated with a
dysregulated activation of immune cell function. It can
affect any portion of the GI tract but most commonly affects
the terminal small intestine and colon [5]. Current treat-
ments for subjects with Crohn’s disease consist of cortico-
steroids, immunosuppressives (e.g., methotrexate, cyclospor-
ine, mercaptopurine and azathioprine), and tumour necrosis
factor inhibitors (e.g., infliximab, adalimumab and certolizumab).
Although there have been recent advances in the treatment of
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patients with Crohn’s disease [6], there is still an unmet
medical need for new therapies [5, 7]. Currently, patients with
Crohn’s disease usemultiple prescription and non-prescription
medications to treat their inflammatory bowel disease (IBD)
symptoms and other systemic and non-IBD disease-related
conditions (e.g., diabetes, hypertension, heart disease). Con-
sequently, patients with Crohn’s disease have a potentially
higher risk for drug–drug interactions compared with the
general population [8].
Following oral administration (250 to 1,000 mg), vercirnon
is readily absorbed with a time to maximum concentration
(tmax) of 3–4 h and an estimated half-life between 12 and
17 h [9]. Once absorbed, vercirnon is extensively metabolised
by multiple oxidative and reductive pathways, including cyto-
chrome P450 (CYP) enzymes such as CYP3A4, CYP2C19
and CYP2B6 (ChemoCentryx, data on file). Vercirnon is
passively permeable and unlikely to be a substrate for human
p-glycoprotein transporter protein or other transport proteins,
and its metabolites are highly protein bound (>90 %) with low
uptake of drug-related material into tissues (ChemoCentryx,
data on file). Based on these observations, the potential for
other drugs to have a clinically-significant effect on vercirnon
was predicted to be low.
No clinical studies have been performed to evaluate the
potential for vercirnon to affect the pharmacokinetics (PK) of
other drugs. Due to the high plasma protein binding for
vercirnon and its metabolites, and the relatively low anticipat-
ed liver concentrations estimated from likely therapeutic plas-
ma concentrations (maximum observed concentration [Cmax]
range 3–5 μM for vercirnon and <0.5 μM for metabolites;
ChemoCentryx, data on file), the potential for vercirnon to
significantly affect the clearance of other drugs utilising CYP
enzymes as a primary clearance pathway was considered to be
low. However, the estimated [I]/Ki ratio, where [I] represents
the mean steady-state Cmax value for total drug (bound plus
unbound) following administration of the highest proposed
clinical dose of vercirnon, was between 0.1 and 1.0 for cyto-
chrome P450 enzymes CYP3A4, CYP2C19, and CYP2C8
activity. This indicated a “possible” interaction requiring a
follow-up clinical evaluation [10]. In addition, in vitro studies
showed that vercirnon can inhibit breast cancer resistant pro-
tein (BCRP) and organic anion transporter (OAT) proteins,
specifically OAT1B1, OAT1 and OAT3 (ChemoCentryx and
GlaxoSmithKline, data on file).
It is important to confirm these in vitro findings and char-
acterise the drug interaction profile of vercirnon in humans to
support late-phase clinical trials, as patients with Crohn’s
disease are often prescribed multiple medications, such as
immunosuppressants, GI anti-inflammatory agents, antibi-
otics and pain relievers. This study investigated the potential
effect of steady-state vercirnon on CYP3A4, CYP2C19 and
CYP2C8 activity, plus BCRP and OATP1B1 transporter ac-
tivity, by evaluating the effect of vercirnon co-administration
on the PK of well-established probe substrates for each
enzyme/transporter [11]. As a secondary objective, the sys-
temic exposure of two metabolites: GSK2635622 and
GSK2656694, relative to the parent drug, vercirnon, were
assessed following single and repeat dosing of vercirnon. In
addition, exploratory pharmacogenetic (PGx) evaluations
were conducted to investigate the relationship between genet-
ic variants in drug metabolism and transporter genes, and
inter-individual variability in PK parameters.
Methods
Subjects
A total of 24 subjects were enrolled to ensure that at least 16
subjects would complete the study. Subjects were eligible to
participate if they were a healthy adult male or female,
of non-childbearing potential, 18–55 years of age with
body weight ≥60 kg and body mass index (BMI) within the
19–30 kg/m2 range. Subjects were excluded from the study if
they were pregnant, smoked, or had liver disease, active or
latent tuberculosis, coeliac disease or a positive serologic test
for tissue transglutaminase (tTG), hepatitis B, hepatitis C, or
human immunodeficiency virus (HIV). Subjects were also
excluded if they had drug or alcohol problems, blood pressure
abnormalities, mental/legal incapacities, sensitivities, medical
conditions judged by the principal investigator to be unsuit-
able for the study, or if they had consumed red wine, citrus
fruits, fruit juices, vegetables from the mustard green family or
charbroiled meats within 7 days prior to the first dose of study
medication. No alcohol, caffeine, or concomitant medications
were allowed while in the clinic. All subjects provided written
informed consent before any study-specific procedures were
performed.
The study was conducted in accordance with good clinical
practice and all applicable regulatory requirements under the
Declaration of Helsinki at a single site: Buffalo Clinical Re-
search Center, Buffalo, NY, USA. A local Institutional Re-
view Board reviewed and approved the study.
Study design and treatments
This was an open-label, single-sequence, repeat-dose study
(CCX114671; ClinicalTrials.gov identifier NCT01489943)
designed to evaluate the effect of repeat doses of vercirnon
on the PK of probe substrates of three CYP enzymes and two
transporter proteins in healthy subjects. The probes used to
investigate the enzyme and transporter activity were: midazo-
lam for CYP3A4, pioglitazone for CYP2C8, omeprazole for
CYP2C19, and rosuvastatin for BCRP and OATP1B1. All
probe substrates were administered orally and at doses that
would provide adequate concentrations of parent and/or
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metabolite for the assessment of potential interactions with
vercirnon. The probe compounds were administered in the
morning on the study days outlined in Table 1. Vercirnon
500 mg was administered twice a day (BID), after a meal,
on days 5–14. Eligible subjects were admitted to the clinical
unit on day -1 (day before first dose) and remained in-house
until day 15. On days 1, 2, 3 and 4 they received single doses
of the probe compounds: midazolam 3 mg oral syrup, pioglit-
azone 15 mg tablet, omeprazole 40 mg capsule and
rosuvastatin 10 mg tablet, respectively. This was followed
by vercirnon 2 x 250-mg capsules BID on days 5–10. On
days 11, 12, 13 and 14, in addition to vercirnon 500 mg BID,
subjects also received the probe compound in the same order
as days 1–4.
For each morning dose, subjects were required to fast
overnight. Subjects were served a moderate fat breakfast
(i.e., fed state) consisting of approximately 28 % fat and
700 cal. Thirty minutes after breakfast was served, study
medication was administered with 240 mL of water. For each
evening dose of vercirnon, subjects were also served a stan-
dard meal 30 min prior to dosing. Serial blood samples were
collected over a 24-h period following the administration of
all probe substrates; except for rosuvastatin, where samples
were collected over 48 h. Full details of sample collection and
probe substrate analysis (including validation, precision and
accuracy ranges) are provided in Online Resource 1. Systemic
levels of the probe substrates when co-administered with
vercirnon were compared with systemic levels when the
probes were administered alone. On study days 5–10, single
trough concentrations were collected immediately prior to
dosing. Additionally, a subset of subjects volunteered to have
serial blood samples collected over 24 h on study days 5 and
10 for analysis of vercirnon and its metabolites, GSK2635622
and GSK2656694. All subjects returned to the unit for a
follow-up visit within 7–10 days after the last dose of study
medication before being discharged from the study. The total
duration of a subject’s participation in the study, including
screening (∼30 days), treatment and the follow-up visit was
approximately 54 days.
Sample size considerations
The potential effect of vercirnon on the probe substrates
evaluated in this study was assessed by comparing the ratio
of area under the concentration curve from zero to infinity
(AUC0–∞) of the probe substrate in combination with
vercirnon (test) to the AUC0–∞ of the probe substrate alone
(reference). The precision for the comparison of interest was
estimated, using a sample size of 16 subjects and based on the
largest average estimate of within-subject variability (%CVw)
for the CYP450 substrates to be studied (28.0 % for
rosuvastatin AUC0–∞; GlaxoSmithKline, data on file). Point
estimates and corresponding 90 % confidence intervals (CIs)
were constructed for the differences between the mean of the
test and reference treatments (the comparison of interest). The
estimated precision is no more than 19 % of the observed
point estimate, where precision is expressed as the half-width
of the 90 % CI. For a point estimate of one, the corresponding
90 % CI for the ratio of geometric means would be 0.84–1.19.
This calculation was based on the loge-scale and a two-tailed
procedure with a type I error rate of 10 %. A total of 24
subjects were enrolled to ensure 16 patients would complete
the study.
A sensitivity analysis was to be conducted in the event that
the %CVw estimates were greater than expected. For the
%CVw in the upper range of 35 %, it was estimated that the
precision for the comparisons of interest would be no more
than 23 % of the observed point estimate (i.e., the 90 % CI for
the ratio of geometric means would be 0.81–1.23, with a point
estimate of one). This calculation was based on the loge-scale
and a two-tailed procedure with a Type I error rate of 10 %.
Study population
The ‘safety population’ consisted of all subjects who received
at least one dose of study medication. The ‘PK population’
included subjects in the ‘safety population’ with PK samples
adequate for calculation of PK parameters. The ‘day 5 and day
10 population’ excluded subjects from the PK population who
had multiple PK samples collected on day 5 and day 10. The
‘PGx population’ excluded subjects who were predicted to be
poor metabolisers or have potentially reduced transporter
activity based on genotyping.
Pharmacokinetic analysis
Plasma concentration time data for all probe substrates, vercirnon
and metabolites were analysed by non-compartmental methods
using WinNonlin® v5.3 (PharSight, a Certara Company, St
Louis, MO). From the concentration time data for each
probe compound, the AUC0–∞, the AUC time curve
from time zero (pre-dose) to last time of quantifiable
concentration (AUC0–t), Cmax, time of occurrence of
Table 1 Summary of treatment administrations
Study day Probe and/or study drug
Day 1 Midazolam 3 mg
Day 2 Pioglitazone 15 mg
Day 3 Omeprazole 40 mg
Day 4 Rosuvastatin 10 mg
Day 5 through day 10 Vercirnon [500 mg BID]
Day 11 Vercirnon [500 mg BID] + midazolam 3 mg
Day 12 Vercirnon [500 mg BID] + pioglitazone 15 mg
Day 13 Vercirnon [500 mg BID] + omeprazole 40 mg
Day 14 Vercirnon [500 mg BID] + rosuvastatin 10 mg
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Cmax (tmax), and apparent terminal phase half-life (t1/2)
(where data were available) were determined following
administration with and without vercirnon.
For vercirnon and its two metabolites, the AUC time curve
over the dosing interval (AUC0–τ), Cmax and tmax were deter-
mined in the subset of six subjects who had serial PK sam-
pling on days 5 and 10. Vercirnon accumulation following
repeat dosing was determined by calculating the accumulation
ratio (Ro) for AUC0–τ and comparing the Cmax for day 10with
day 5. The ratio of metabolite AUC0–τ to vercirnon AUC0–τ
on day 5 and day 10 was calculated after converting the
AUC0–τ values to appropriate molar units.
Statistical analysis
Probe assessment
The potential effect of vercirnon on the probe substrates
evaluated in this study was assessed by comparing the ratio
of AUC0–∞ of the probe substrate with and without concom-
itant vercirnon. The primary endpoint for all probe substrates
(except omeprazole) was the ratio of AUC0–∞ for each of the
probe substrates when administered with and without con-
comitant vercirnon. Due to the high inter- and intra-subject
variability associated with omeprazole PK [12], its metabolite
(5-OH-omeprazole) was also quantified in plasma and the
ratio of omeprazole metabolite to parent was calculated to
normalise for the variability associated with the absorption
and metabolism of omeprazole. The statistical endpoint for
omeprazole was calculated from the AUC0–∞ ratio of
metabolite:parent, both with and without concomitant
vercirnon. Following loge-transformation, the primary end-
points were separately analysed using a mixed-effects model.
Treatment was fitted as a fixed effect and subject as a random
effect. Point estimates and their associated 90 % CI were
constructed for the ratios, by back transforming the respective
difference between the treatment least squares (LS) means and
the associated 90 % CI.
Vercirnon steady-state analysis
Trough concentration (Cτ) samples collected from all 24
subjects on study days 6–11 were used to assess attainment
of steady-state. Individual plasma vercirnon pre-dose con-
centrations were obtained and the mean (+ standard devia-
tion [SD]) and median (range) were plotted and
summarised by day. A mixed-effects model with subject
as a random effect and day as a fixed effect was performed
on the loge-transformed Cτ data. Day was treated as a
continuous variable in the model. Achievement of plasma
vercirnon steady state was assessed by calculating the 90 %
CI of the slope of the linear regression of pre-dose Cτ versus
day. To claim steady state was reached, the slope estimate
needed to be close to zero or the 90%CI for the slope estimate
needed to include zero.
Safety
Safety and tolerability parameters were assessed by the mea-
surement of vital signs, cardiac monitoring, adverse event
(AE) assessments and clinical laboratory tests. The two
vercirnon metabolites (GSK2635622 and GSK2656694) were
assayed and the molar ratio of each metabolite to vercirnon
(parent) concentrations were determined.
Pharmacogenetic analyses
To account for potential inter-patient variability as a result of
genetic polymorphisms, exploratory PGx evaluations were
also conducted. Exploratory analyses included PK parameters
in a sub-population of subjects who had no common genetic
variations in the CYP enzymes or BCRP/OATP1B1 trans-
porters that could negatively impact their activity (the PGx
population). The ‘Affymetrix DMET-Plus’ genotyping array
[13] was used to genotype common genetic variants in
CYP3A4/3A5 , CYP2C8 , CYP2C19 , SLCO1B1 (OATP1B1)
and ABCG2 (BCRP). Subjects carrying genetic variants
which predicted poor metabolism or reduced activity for the
respective CYP enzymes or transporters were excluded from
the relevant exploratory PGx analysis, thereby creating sub-
populations with fewer confounding factors.
Results
Subjects
A total of 24 subjects (23 males: 1 female) enrolled and
completed the study. Subjects had a mean (±SD) age of
33±10.6 years (range 19–54 years), weighed 78.7±12.8 kg
(range 61.0–109.9 kg) and had a mean (±SD) BMI of
25.68±2.77 kg/m2 (range 20.1–30.2 kg/m2). Sixteen sub-
jects (67 %) were Caucasian or of European heritage and
8 (33 %) were African-American or of African heritage.
All 24 (100 %) subjects enrolled were included in the
‘safety population’ and the ‘PK population’. The ‘day 5 and
day 10 population’ consisted of six subjects whilst the ‘BCRP
PGx’ and ‘OATP1B1 PGx’ populations consisted of 19 and
22 subjects, respectively.
Pharmacokinetics
Probe and treatment comparisons
The plasma PK parameters for probe substrates midazolam,
pioglitazone, omeprazole, 5-OH-omeprazole and rosuvastatin
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administered with and without concomitant vercirnon are
summarised in Table 2. PK parameters for each of the probe
substrates were similar irrespective of whether they were ad-
ministered alone or in combination with vercirnon. AUC0–∞
variability for each of the probe substrates are presented in
Table 3. In the case of omeprazole, the%CVw for theAUC0–∞
treatment comparison was 54.3 % (Table 3). The %CVw was
greater than the 28 % used to estimate sample size and the
precision of the comparison of interest. However, using the
planned ratio of the 5-OH-omeprazole metabolite AUC0–∞ to
omeprazole AUC0–∞, the %CVw was reduced to 13.7 %.
The %CVw for AUC0–∞ for midazolam, pioglitazone,
rosuvastatin and 5-OH-omeprazole:omeprazole, (with and with-
out vercirnon) ranged from 11.6 % to 21.7 %. The 90 % CI of
the geometric LS mean ratios for midazolam, pioglitazone,
rosuvastatin, and 5-OH-omeprazole:omeprazole all fell within
the 0.80–1.25 range of standard bioequivalence (Table 3).
Vercirnon and metabolites—accumulation and steady-state
assessment
A summary of the derived vercirnon PK parameters on study
day 5 (day 1 of vercirnon dosing) and study day 10 (day 6 of
vercirnon repeat dosing) for the 6 subjects who participated in
the serial PK sampling are presented in Table 4. The average
accumulation for vercirnon in terms of AUC0–τ and Cmax on
day 10, compared with day 5, was 14% and 3%, respectively.
Concentration-time profiles for the metabolites GSK2656694
and GSK2635622 paralleled that of vercirnon (Fig. 1) and
appear (by visual inspection) to accumulate and reach steady-
state after 2 days of dosing (∼48 h). The statistical assessment
of vercirnon steady-state, following daily dosing of vercirnon
500 mg twice daily for 6 days, confirmed that plasma concen-
trations of vercirnon achieved steady-state (90 % CI of the
slope estimates included zero) by the end of the second day of
Table 2 Summary of plasma probe pharmacokinetic parameters after administration of probe with and without vercirnon
Treatment N AUC0-∞
a AUC0-t Cmax t1/2 tmax
b
(ng*hr/mL) (ng*hr/mL) (ng/mL) (hr) (hr)
Midazolam alone 24 35.9 34.1 9.56 3.50 0.5
Day 1 (31.0, 41.7) (29.5, 39.5) (8.33, 10.99) (2.97, 4.12) (0.5–2.0)
Midazolam + vercirnon 24 33.0 31.4 8.60 3.54 0.5
Day 11 (29.5, 36.8) (28.1, 35.2) (7.52, 9.83) (2.99, 4.18) (0.5–2.0)
Pioglitazone alone 24 5248.9 4595.9 528.3 6.6 3.0
Day 2 (4685, 5881) (4068, 5193) (471.7, 591.7) (5.8, 7.4) (1.5–4.0)
Pioglitazone + vercirnon 24 5284.5 4715.8 569.4 5.3 3.0
Day 12 (4835, 5775) (4230, 5257) (522.9, 619.9) (4.9, 5.8) (1.5–4.0)
Omeprazole alone 24 634.9c 616.4e 256.5 1.08c 4.0
Day 3 (453.0, 889.9) (452.9, 839.1) (179.6, 366.5) (0.94, 1.25) (1.5–24.0)
Omeprazole + vercirnon 24 626.8e 617.4 275.4 1.18e 4.0
Day 13 (466.9, 841.3) (465.3, 819.3) (208.9, 363.0) (0.99, 1.40) (1.0–6.0)
5-OH-omeprazole alone 24 692.8d 671.8e 210.2 1.60d 4.0
Day 3 (547.3, 877.0) (535.0, 843.6) (151.5, 291.5) (1.36, 1.88) (1.5–24.0)
5-OH-omeprazole + vercirnon 24 653.0c 660.9 238.7 1.79c 4.0
Day 13 (576.4, 739.8) (587.3, 743.8) (194.9, 292.4) (1.43, 2.25) (1.0–6.0)
Rosuvastatin alone 24 28.6 25.3 2.38 13.15 4.0
Day 4 (22.9, 35.7) (20.1, 31.8) (1.95, 2.90) (10.96, 15.79) (1.0–6.0)
Rosuvastatin + vercirnon 23e 28.4 25.1 2.50 11.99 3.0
Day 14 (23.0, 35.0) (19.9, 31.7) (1.97, 3.18) (10.27, 13.99) (1.0–6.0)
Numbers of subjects are different because AUC values could not be calculated in a few instances
AUC0-∞ area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time, AUC0-t area under the concentration-time curve
from time zero (pre-dose) to last time of quantifiable concentration, Cmax maximum observed concentration, t1/2 apparent terminal phase half-life, tmax
time of occurrence of Cmax
a Data presented as geometric mean (95 % confidence intervals) except for tmax
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dosing. When vercirnon was at steady-state (day 10), the
mean AUC0–τ for the metabolites GSK2635622 and
GSK2656694 averaged 1.1 % and 2.6 % of parent AUC0–τ,
respectively. Based on the data from the six subjects in this
study, neither metabolite would be predicted to exceed 10 %
of parent exposure.
Safety
Vercirnon, along with the four probe substrates, was well
tolerated in the 24 subjects who completed all treatments over
the course of 14 days. There were no deaths, non-fatal serious
AEs, early withdrawals due to AEs or pregnancies. A total of
43 post-treatment AEs were reported during the study. The
most frequent AE was somnolence, which was reported by 13
subjects on 19 occasions. In all cases, subjects were being
treated with either midazolam alone or a combination of mid-
azolam and vercirnon. Eight gastrointestinal AEs (dyspepsia
[n =3], nausea [n =2], and one each of abdominal pain, diar-
rhoea and gastro-oesophageal reflux) were reported by seven
subjects. Three of these AEs were classified as potentially
drug-related by the investigator, though only two (abdominal
pain, dyspepsia) were reported during treatment with vercirnon
alone. Other non-gastrointestinal AEs that occurred in more
than one subject were headache (n =4), dizziness (n =2), and
abnormal dreams (n =2). All AEs were classified as mild in
intensity with the exception of two clinical chemistry labora-
tory AEs in one subject, which were judged by the investigator
to be of severe intensity, but unrelated to study treatment. One
subject who had normal aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) levels throughout the study
and at dischargewas also recorded as having elevated ALTand
Table 3 Statistical summary of plasma AUC0−∞ treatment comparisons for probe interaction assessments (PK population)






90 % CI CVw
Test : Reference (%)
Midazolam + Vercirnon Midazolam Midazolam AUC0-∞ 24 33.0 24 35.9 0.92 (0.85, 0.99) 16.0
Pioglitazone + Vercirnon Pioglitazone Pioglitazone AUC0-∞ 24 5284.5 24 5248.9 1.01 (0.95, 1.07) 11.6
Omeprazole + Vercirnon Omeprazole Omeprazole AUC0-∞ 23 634.8 21 638.0 0.99 (0.76, 1.31) 54.3
Omeprazole + Vercirnon Omeprazole 5-hydroxyomeprazole AUC0-∞ 21 655.3 22 692.2 0.95 (0.76, 1.18) 42.9
Omeprazole + Vercirnon Omeprazole 5-hydroxyomeprazole AUC0-∞
/omeprazole AUC0-∞
21 1.015 21 1.004 1.01 (0.93, 1.09) 13.7
Rosuvastatin + Vercirnon Rosuvastatin Rosuvastatin AUC0-∞ 23 28.1 24 28.6 0.98 (0.88, 1.09) 21.7
PK pharmacokinetic, Ref reference, Geom geometric, LS least squares, CI confidence interval, CVw coefficient of variation within subject
Table 4 Summary of plasma vercirnon and metabolite PK parameters after administration of a single dose of vercirnon 500 mg (study day 5) and after
vercirnon 500 mg BID for 6 days (study day 10)
Analyte/day N AUC0–τ
a (ng*hr/mL) Cmax (ng/mL) tmax
b Ro Ro
(hr) AUC0–τ Cmax
day 10/day 5 day 10/day 5
Vercirnon 6 7227 931 4.0
Day 5 (5554, 9404) (711, 1219) (4–6)
Vercirnon 6 8231 959 2.5 1.14 1.03
Day 10 (6657, 10,177) (783, 1174) (0–4) (0.96, 1.35) (0.89, 1.19)
GSK2635622 5 6.25 2.64 11.92
Day 5 (1.57, 24.9) (1.11, 6.28) (10.0 −11.9)
GSK2635622 6 65.8 7.35 3.50 NC NC
Day 10 (28.5, 152.5) (3.36, 16.06) (0.0–11.9)
GSK2656694 6 4.72 2.85 11.92
Day 5 (1.73, 12.88) (1.46, 5.54) (10.0–11.9)
GSK2656694 6 185.0 21.15 0.50 NC NC
Day 10 (112.1, 305.2) (13.63, 32.82) (0.0–10.0)
AUC0–τ area under the concentration-time curve over the dosing interval, Cmax maximum observed concentration, tmax time of occurrence of Cmax,
Ro accumulation ratio, NC not calculated
a Data presented as geometric mean (95 % confidence intervals) except for tmax
b tmax presented as median (min-max)
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AST values at an unscheduled visit (when the subject returned
to the clinic to screen for another clinical study). This was
16 days after the last dose of vercirnon and rosuvastatin, when
drug concentrations would be negligible. Additional informa-
tion provided by the investigator confirmed that the subject
remained well and that the transaminase levels had returned to
normal over a few weeks.
All AEs resolved by the end of the study and no other
clinically significant laboratory findings, haematology, vital
signs, or electrocardiogram (ECG) changes were observed.
Pharmacogenetics
PK analyses were performed for the BCRP and
OATP1B1 transporter PGx sub-populations only, as no
subjects were predicted to be poor metabolisers based
on their CYP3A4/3A5, CYP2C8 or CYP2C19 genotype.
An evaluation of PK endpoints in the BCRP (n =19)
and OATP1B1 (n =22) PGx populations revealed no signifi-
cant difference in PK outcomes compared with the overall
study population. All geometric mean ratios were between
0.98 and 1.01 and the 90 % CI were between 0.86 and 1.13.
Discussion
Assessing potential drug–drug interactions is a key aspect in
the development of any pharmaceutical treatment, especially
in the assessment of safety and effectiveness. The objective of
drug–drug interaction studies is to determine the potential for
interactions and whether these may require dosage adjust-
ments or additional therapeutic monitoring to maintain treat-
ment efficacy and/or mitigate risk. Preclinical studies identi-
fied a potential interaction between vercirnon and CYP3A4,
CYP2C19, and CYP2C8 activity with [I]/Ki ratios between
0.1 and 1.0, which would require a follow-up clinical evalu-
ation in line with the recommendations in the US Food and
Drug Administration Guidance for Industry: Drug Interaction
Studies [10], as well a potential interaction with the transporter
proteins BCRP, OAT1B1, OAT1 and OAT3 (ChemoCentryx
and GlaxoSmithKline, data on file). Since the in vitro results
were similar, these studies did not help to prioritise the eval-
uation of clinical drug interactions. Given the number of
potential interactions, this study was designed to utilise probe
substrates to evaluate the effect of vercirnon on the activity of
all the CYP enzymes and transporter proteins of interest in
healthy adult subjects.
Ideally, selected probe substrates should be the most sen-
sitive and specific substrates for the CYP enzymes or transport
proteins under investigation. Midazolam and omeprazole are
recognised as sensitive probe substrates for CYP3A4 and
CYP2C19, respectively: their AUC0–∞ values would be
expected to increase by 5-fold when co-administered with a
known CYP3A4 or CYP2C19 inhibitor. Pioglitazone was
used as the probe substrate for CYP2C8 instead of the more
sensitive probe substrate repaglinide, because it has a lower
potential for hypoglycaemia in healthy non-diabetic subjects,
and because it is also a substrate for OATP1B1; in vitro studies
have shown that vercirnon has the potential to inhibit
OATP1B1 transport proteins. CYP2C8 and CYP3A4 are the
main enzymes catalysing the transformation of pioglita-
zone. Co-administration of pioglitazone with gemfibrozil
(Ki = 69–75 μM), a strong inhibitor of CYP2C8, signifi-
cantly increases pioglitazone AUC by 3.4-fold [14]. Co-
administration with rifampin, a potent inducer of CYP2C8,
decreases the exposure (AUC) of pioglitazone by 54 % [15].
However, co-administration of pioglitazone with ketocona-
zole, a strong inhibitor of CYP3A4, only increases pioglita-
zone by 34 %. For these reasons, pioglitazone was considered
a suitable probe substrate for CYP2C8.



























Fig. 1 Mean (95 % CI) plasma
concentrations of vercirnon and
metabolites GSK2635622 and
GSK2656694 following
vercirnon 500 mg BID for
6 days (n =6)
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Drug transport proteins affect the concentration of drugs
and metabolites in various tissues and can have a signifi-
cant effect on the safety profile of a drug. Rosuvastatin, an
HMG-CoA reductase inhibitor indicated for the treatment
of hypercholesterolaemia, is recognised as a probe substrate
for multiple transporters: OATP1B1, OATP1B3, OAT3 and
BCRP [11]. Rosuvastatin is actively transported into hepato-
cytes by OATP1B1, resulting in a high first-pass effect and a
low bioavailability (∼20 %). Co-administration of cyclospor-
in, an inhibitor of OATP1B1, increased rosuvastatin AUC by
7-fold [16]. A recent in vitro study suggested that the BCRP
efflux transporter may also play a role in rosuvastatin dispo-
sition [17]. While rosuvastatin may not be able to identify
which transporter protein vercirnon may affect, a negative
result would rule out drug interaction due to several trans-
porters and confirm rosuvastatin as an anti-cholesterol agent
that may be co-administered with vercirnon.
Overall, administration of midazolam, pioglitazone, omep-
razole, or rosuvastatin following repeat dosing of vercirnon
had no significant effect on the systemic exposure (AUC0–∞)
of each probe. This indicates that vercirnon exerted no sub-
stantial clinical effect on the activity of CYP enzymes
CYP3A4, CYP2C8, CYP2C19 or on BCRP and OAT1B1
transporter activity.
In the case of omeprazole, the %CVw for the AUC0–∞
treatment comparison was particularly high (54.3 %). This
could be an outlier effect, as one subject recorded the lowest
exposure when receiving omeprazole alone, followed by one
of the highest exposures when he received omeprazole in
combination with vercirnon. Additional statistical analysis,
excluding this subject from the omeprazole analysis, reduced
the %CVw for omeprazole to 27.8 %. However, excluding
this subject did not have a substantial impact on the overall
findings. While safety and tolerability data were collected in
this study, it must be noted that the study was not powered to
assess these outcomes, and any interpretation should be made
with caution. Nevertheless, the results of this study suggest
that short-term exposure to vercirnon appears to have a
favourable safety and tolerability profile. This requires confir-
mation in future studies. In addition, although there is a low
predicted potential for vercirnon to interact with other drugs,
or vice versa, this study did not directly assess the interaction
of vercirnon with current treatments for Crohn’s disease, such
as corticosteroids, immunosuppressives, and tumour necrosis
factor inhibitors. Vercirnon is a distinct class of compound to
these treatments, and so the potential for combination therapy
warrants investigation in future studies.
In conclusion, the results of this study confirm and extend
those from in vitro studies, demonstrating that vercirnon is
unlikely to affect the clearance of other drugs metabolised by
CYP3A4, CYP2C8 and CYP2C19 enzymes, or affect the
transport activity of BCRP or OATP1B1. This indicates that
there is a low risk of drug–drug interactions with repeat doses
of vercirnon, supporting its use in Phase III clinical trials.
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